HERSCHORN, Sender; NAZIR, Jameel; RAMOS, Barbara; HAKIMI, Zalmai. Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada. Canadian Urological Association Journal, [S. l.], v. 11, n. 3-4, p. 123–30, 2017. DOI: 10.5489/cuaj.4114. Disponível em: https://cuaj.ca/index.php/journal/article/view/4114. Acesso em: 5 may. 2026.